» Articles » PMID: 25161388

Impact of Stated Barriers on Proposed Warfarin Prescription for Atrial Fibrillation: a Survey of Canadian Physicians

Overview
Journal Thromb J
Publisher Biomed Central
Date 2014 Aug 28
PMID 25161388
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke. Despite proven effectiveness, warfarin remains an under-used treatment in atrial fibrillation patients. We sought to study, across three physician specialties, a range of factors that have been argued to have a disproportionate effect on treatment decisions.

Methods: Cross-sectional survey of Canadian Family Doctors (FD: n = 500), Geriatricians (G: n = 149), and Internal Medicine specialists (IMS: n = 500). Of these, 1032 physicians were contactable, and 335 completed and usable responses were received. Survey questions and clinical vignettes asked about the frequency with which they see patients with atrial fibrillation, treatment practices, and barriers to the prescription of anticoagulants.

Results: Stated prescribing practices did not significantly differ between physician groups. Falls risk, bleeding risk and poor patient adherence were all highly cited barriers to prescribing warfarin. Fewer geriatricians indicated that history of patient falls would be a reason for not treating with warfarin (G: 47%; FD: 71%; IMS: 72%), and significantly fewer changed reported practice in the presence of falls risk (χ (2) (6) = 45.446, p < 0.01). Experience of a patient having a stroke whilst not on warfarin had a significant impact on vignette decisions; physicians who had had patients who experienced a stroke were more likely to prescribe warfarin (χ (2) (3) =10.7, p = 0.013).

Conclusions: Barriers to treatment of atrial fibrillation with warfarin affect physician specialties to different extents. Prior experience of a patient suffering a stroke when not prescribed warfarin is positively associated with intention to prescribe warfarin, even in the presence of falls risk.

Citing Articles

Prescribing of anticoagulation for atrial fibrillation in primary care.

Martinez K, Eckman M, Pappas M, Rothberg M J Thromb Thrombolysis. 2022; 54(4):616-624.

PMID: 35449383 PMC: 10481404. DOI: 10.1007/s11239-022-02655-z.


Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.

Willey V, Franchino-Elder J, Fu A, Wang C, Sander S, Tan H BMJ Open. 2018; 8(6):e020676.

PMID: 29961012 PMC: 6042605. DOI: 10.1136/bmjopen-2017-020676.


Physician decision making in anticoagulating atrial fibrillation: a prospective survey of a physician notification system for atrial fibrillation detected on cardiac implantable electronic devices of patients at increased risk of stroke.

Cloutier J, Khoo C, Hiebert B, Wassef A, Seifer C Ther Adv Cardiovasc Dis. 2018; 12(4):113-122.

PMID: 29528778 PMC: 5941669. DOI: 10.1177/1753944717749739.


Evaluating the potential for pharmacists to prescribe oral anticoagulants for atrial fibrillation.

Sandhu R, Guirguis L, Bungard T, Youngson E, Dolovich L, Brehaut J Can Pharm J (Ott). 2018; 151(1):51-61.

PMID: 29317937 PMC: 5755820. DOI: 10.1177/1715163517743269.


A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.

Brown J, Shewale A, Dherange P, Talbert J Drugs Aging. 2016; 33(6):427-36.

PMID: 27154397 DOI: 10.1007/s40266-016-0369-y.


References
1.
Baczek V, Chen W, Kluger J, Coleman C . Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract. 2012; 13:5. PMC: 3395868. DOI: 10.1186/1471-2296-13-5. View

2.
Poses R, Anthony M . Availability, wishful thinking, and physicians' diagnostic judgments for patients with suspected bacteremia. Med Decis Making. 1991; 11(3):159-68. DOI: 10.1177/0272989X9101100303. View

3.
Gage B, Yan Y, E Milligan P, Waterman A, Culverhouse R, Rich M . Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151(3):713-9. DOI: 10.1016/j.ahj.2005.04.017. View

4.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F . New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012; 59(16):1413-25. DOI: 10.1016/j.jacc.2012.02.008. View

5.
Feinberg W, Blackshear J, Laupacis A, Kronmal R, Hart R . Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995; 155(5):469-73. View